By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Enterin Inc. 

3624 Market Street
Suite 517
Philadelphia  Pennsylvania  19104  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease.

We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease.

Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (aS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease.

Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.

YEAR FOUNDED:

2016

LEADERSHIP:

Founder, Chairman & CEO: Michael Zasloff, MD, PhD

Co-founder, President & CMO: Denise Barbut, MD, FRCP

Co-Founder, Senior VP, R&D: William Kinney, PhD

CFO: Nancy Ness

Senior Advisor, Regulatory Affairs: Brian Harvey, MD, PhD

SCIENCE:

Please click here for Enterin's science.


Key Statistics


Email:
Ownership: Private

Web Site: Enterin
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->